The US Food and Drug Administration (FDA) has approved Switzerland-based Novartis' Beovu (brolucizumab) injection intended for the treatment of wet age-related macular degeneration (AMD), it was reported yesterday.
The product, which is also known as RTH258, is now the first anti-VEGF (Vasco Endothelial Growth Factor) to be approved by the regulator.
According to the company, the drug can offer greater fluid resolution compared to aflibercept. It is also said to have the ability to maintain eligible wet AMD patients on a dosing interval of three months immediately after a three-month loading phase with efficacy. The drug is a humanised single-chain antibody fragment, whose structure is claimed to result in a small molecule with potent inhibition of, and high affinity to, all VEGF-A isoforms.
The approval was based on the findings of two phase three trials called HAWK and HARRIER. The Novartis wet AMD candidate delivered non-inferiority in comparison to aflibercept in the two trials in mean change in best-corrected visual acuity (BCVA) in the first year of treatment.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial